Subcutaneous · GLP-1 / glucagon dual
Survodutide
31 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
31
Ongoing
9
Recruiting
4
Completed
22
Sites
1,314
Countries
46
Endpoints
330
Composite endpoints
14
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
19
Phase 2
4
Phase 3
8
Trials by status
Not yet recruiting
1
Recruiting
4
Active, not recruiting
4
Completed
22
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Weight & body composition
88
MASH / liver
73
Safety / tolerability / PK
53
Cardiometabolic biomarkers
51
Glycemic / diabetes
27
Cardiovascular outcomes
17
Patient-reported / QoL
6
Other (unclassified)
6
Renal / kidney
5
Heart failure
4
Top 20 metrics across this asset's endpoints
AUC₀-∞Safety/PK
21
CmaxSafety/PK
19
HbA1c, changeGlycemic
16
Body weight, % changeWeight
13
Waist circumference, changeWeight
13
ALT, changeMASH
10
≥5% weight-loss respondersWeight
9
≥10% weight-loss respondersWeight
9
Body weight, absolute change (kg)Weight
9
Systolic BP, changeBiomarker
9
Diastolic BP, changeBiomarker
9
Liver fat content, changeMASH
9
AST, changeMASH
8
≥15% weight-loss respondersWeight
7
MRI-PDFF ≥30% respondersMASH
7
Free fatty acids, changeBiomarker
6
Lean massWeight
6
Liver stiffness (VCTE), changeMASH
6
Visceral fat, changeWeight
5
Fibrosis ≥1-stage improvement, no MASH worseningMASH
5
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
31 of 31
Showing 1-25 of 31 trials